<h4>Objective</h4>The objective of this work was to investigate the efficacy and safety of stapokibart, an anti-IL-4R<i>α</i> monoclonal antibody, in patients under 18 years of age with moderate-to-severe seasonal allergic rhinitis (SAR).<h4>Methods</h4>A retrospective analysis was conducted on 20 children with severe SAR who received stapokibart treatment during spring (March-April) and autumn (August-October) of 2025. This evidence concerns the gene IL4R and allergic rhinitis.